Authored by Karl Simpson
Annalisa Jenkins joins the Board of Biothera, the immuno-oncology company. Dr. Jenkins, until recently the Global Head of R&D at Merck Serono and presently the Chairman or TransCelerate. Biothera’s product, Imprime PGG, is a novel cancer immunotherapy that engages and directs the innate immune system to kill cancer cells. Dr. Jenkins, previously an R&D executive with BMS, will bring specific immune-oncology drug development experience to the Biothera Board.
Katrine Bosley, former CEO of Avila Therapeutics which was acquired by Celgene, has been appointed to Boston-based Editas Medicine. The company has a stellar line up of investor in Third Rock Ventures, Polaris and Flagship Ventures. After guiding Avila to a successful exit, Katrine Bosley has gained attention across the sector as a key name in biotech leadership.
Global biotechnology company, Amgen Inc, announced that from July 21st, David Meline will join the company as executive vice president and chief financial officer. Meline recently served as CFO at 3M and prior to that served General Motors for more than two decades.
Oxford BioTherapeutics appoints Dr. Keith E Wilson as Chief Scientific Officer. The Oxford, UK based biotech company developing antibody drug conjugates (ADCs) for the cancer therapies market, have hired Dr. Keith E Wilson as CSO from Abbvie where he the Global Leader of antibody drug conjugates.
The Swiss based biotechnology company Genkyotex announced the appointment of Dr Daniel Elger as Chief Financial Officer and Chief Development Officer. Dr Elger joins from London based e-therapeutics where he was CFO and Board Director.
Mr Frank Thomas has joined the board of directors at Boston based biopharma company Zafgen. Zafgen are developing drugs for the treatment of unmet medical needs in severely obese patients.
Kymab, the UK based monoclonal antibody expert announced two new senior appointments. Mr Steven Arkinstall joining as CSO and Mr Nigel Clarke joining as Vice President and Head of Business Development.